ESMO Guides for Patients: Disclaimer and declaration of interest

Disclaimer

ESMO Guides for Patients are prepared in collaboration with the Anticancer Fund as a service to patients, to help patients and their relatives better understand the nature of their cancer type and understand the best treatment choices available. Please note that information in these Guides for Patients does not replace a medical consultation. ESMO recommends that patients ask their doctors about what tests or types of treatments are needed for their type and stage of disease.

Patient information based on the ESMO Clinical Practice Guidelines - Conflict of interest disclosures

  • Aglione Antonio: No conflicts of interest to declare
  • Aguarón Alfonso: No disclosure at time of going online
  • Allum William: No conflicts of interest to declare
  • Apostolidis Kathi: A volunteer cancer patient advocate and the Vice-President of ECPC, the European Cancer Patient Coalition. ECPC has received support to carry its action plan from AbbVie, Amgen, AstraZeneca, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly & Co, Gilead, Helsinn, Ipsen, Johnson & Johnson, Merck, MSD, Novartis, Pfizer, and Roche.
  • Arnold Dirk: Research grants – Roche, Sanofi
  • Baccarani Michele: Honoraria from Novartis, Bristol-Myers Squibb, Pfizer and Ariad for participation to advisory boards and as a speaker at scientific and educational meetings.
  • Bayne Louise: No disclosure at time of going online
  • Beveridge Jane: No conflicts of interest to declare
  • Blay Jean-Yves: No conflicts of interest to declare
  • Boland Greet: No conflicts of interest to declare
  • Bouche Gauthier: No conflicts of interest to declare
  • Bouguet Guy: No disclosure at time of going online
  • Bellmunt Joaquim: Consultant or Advisory Role - Lilly, Pierre Fabre and Sanofi Aventis
  • Billiau An: Medical writer of Celsus Medical Writing LLC. – Honoraria from Anticancer Fund
  • Bosman Patricia: No conflicts of interest to declare
  • Bramley Claire: No conflicts of interest to declare
  • Buske Christian: Research funds: Roche, Janssen; Speaker’s bureau: Roche, Janssen, Pfizer
  • Cardoso Fatima: Receipt of honoraria or consultation fees: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, Roche, Sanofi, Seattle Genetics, Teva
  • Casali Paolo: Consultancy/Honoraria: Amgen Domplé, ARIAD, Bayer, GlaxoSmithKline, Infinity, Janssen Cilag, Merck Sharp & Dohme, Novartis, Pfizer, PharmaMar, Sanofi
  • Cascinu Stefano: No conflicts of interest to declare
  • Colia Vittoria: No conflicts of interest to declare
  • Colombo Nicoletta: Consultancy/Honoraria from GlaxoSmithKline, Merck Serono, Roche, Amgen, Pharma Mar, Clovis
  • Crinò Lucio: No conflicts of interest to declare
  • Cunningham David: Research funding - Roche and Amgen
  • D’Addario Giannicola: No conflicts of interest to declare
  • De Lorenzo Francesco: A volunteer cancer patient advocate and the President of ECPC, the European Cancer Patient Coalition. ECPC has received support to carry its action plan from AbbVie, Amgen, AstraZeneca, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly & Co, Gilead, Helsinn, Ipsen, Johnson & Johnson, Merck, MSD, Novartis, Pfizer, and Roche.
  • Denis Louis: No conflicts of interest to declare
  • Diamanti Orejeta: No conflicts of interest to declare
  • Douillard Jean-Yves: No conflicts of interest to declare
  • Dreyling Martin: Advisory Board: Bayer, Celgene, Gilead, Janssen, Pfizer; Consultancy/Honorari: Celgene, Janssen, Mundipharma, Pfizer, Roche; Research funding to the institution: Celgene, Janssen, Pfizer, Mundipharma, Roche.
  • Dummer Reinhard: Research funding - Astra Zeneca, Novartis, Cephalon, Merck Sharp & Dhome, Transgene, Bristol-Myers Squibb, Roche, GlaxoSmith Klein, Bayer; Consultant or Advisory Board: Astra Zeneca,Novartis, Cephalon, Merck Sharp & Dhome, Transgene, Genta, Bayer, Roche, Bristol-Myers Squibb, GlaxoSmith Klein, Spirig.
  • Felip Enriqueta: Consultancy/Honoraria – Ely Lilly, GlaxoSmith Klein, Phizer, Roche, Boehringer Ingelheim
  • Fenlon Deborah: No disclosure at time of going online
  • Fey Martin: No conflicts of interest to declare
  • Florindi Francesco: No conflicts of interest to declare
  • Fowler Matthew: No conflicts of interest to declare
  • Freitas Jorge: No conflicts of interest to declare
  • Gardini Ivan: No conflicts of interest to declare
  • Geissler Jan: No disclosure at time of going online
  • Giles Rachel H.: Speakers’ Honoraria from Ipsen and Novartis. The IKCC receives project and educational funds from BMS, Ipsen, Exelixis, MSD, Pfizer, Novartis, Eisai, and Roche
  • Glimelius Bengt: No conflicts of interest to declare
  • Gonzato Ornella: No conflicts of interest to declare
  • Grce Magdalena: No conflicts of interest to declare
  • Haie-Meder Christine: No conflicts of interest to declare
  • Haanen John: Honoraria from Amgen, Merck, MSD, Helsinn, Tesaro and Hexaland; A member of the advisory board of Merck, MSD, Helsinn and Tesaro
  • Hewitt Julie: No conflicts of interest to declare
  • Horwich Alan: His institution is inventor of abiraterone and receives royalty payments; no personal conflicts.
  • Jelic Svetislav: No conflicts of interest to declare
  • Jewel Anna: No conflicts of interest to declare
  • Jezdic Svetlana: No conflicts of interest to declare
  • Jordan Karin: Honoraria from Amgen, Merck, MSD, Helsinn, Tesaro and Hexaland; A member of the advisory board of Merck, MSD, Helsinn and Tesaro
  • Jost Lorenz: No conflicts of interest to declare
  • Ihlen Regine Deniel: Lung Cancer Europe (LuCE) is a non-profit organisation whose activities are funded by balanced support from BMS and MSD
  • Keilholz Ulrich: Honoraria: Amgen, BMS, GSK, Glycotope, MerckSerono, Merck/MSD, Pfizer; Research support: Pfizer, MerckSerono, Innate, Sirtec.
  • Khort Holbrook: No conflicts of interest to declare
  • Kinneally Ada: No conflicts of interest to declare
  • Kirby David: No conflicts of interest to declare
  • Kornek Gabriella: No disclosure at time of going online
  • Kosmidis Paris: No conflicts of interest to declare
  • Labianca Roberto: Research grants – Roche, Sanofi
  • Ladetto Marco: No conflicts of interest to declare
  • Lewington Michelle: No conflicts of interest to declare
  • Licitra Lisa: Advisory Board: Bristol-Myers Squibb, GlaxoSmith Klein, Ely Lilly, Merck-Serono and Amgen; Institutional funds for clinical studies and research activities in which she is involved from EISAI, Exelixis, ly Lilly, Merck-Serono, Amgen; Travel coverages to attend medical meetings Merck-Serono.
  • Marchesi Vanessa: No conflicts of interest to declare
  • Margulies Anita: No conflicts of interest to declare
  • Metro Giulio: Honoraria from Anticancer Fund
  • Michiels Annemie: No conflicts of interest to declare
  • Mitsimponas Nikolaos: No conflicts of interest to declare
  • Moreau Philippe: Advisory Boards and Honoraria: Celgene, Janssen, Takeda, Amgen and Novartis.
  • Mussetti Alberto: No conflicts of interest to declare
  • Okines Alicia: Honorarium and travel support – Roche
  • Oliver Kathy: Honoraria for Healthcare Advisory Board (“HAB” – patient advocacy board) – GlaxoSmithKline; Honoraria for Global Council of the Patient Access to Cancer Care Excellence (PACE) initiative – Eli Lilly; Honoraria as a member of E-PALCO (European Cancer Patient Leaders Council) – Novartis; Honoraria for Worldwide Oncology Advocacy Advisory Board – Bristol-Myers Squibb; Honoraria for Advisory meeting – AbbVie; Honoraria for consultancy – Eli Lilly; Speaker fee: Bayer; Consultancy work EORTC/SPAEN Training Course in “Understanding Clinical Research”; Honoraria for consultancy work SPAEN training course in patient advocacy. KO is a Chair and Co-Director of the International Brain Tumour Alliance (IBTA) that accepted financial support and support in kind either directly or as part of a wider grouping of patient organisations from the following companies and trusts: Accuray, Antisense Pharma, Apogenix, Archimedes, Ark Therapeutics, Astra Zeneca, Boehringer Ingelheim, Brain Tumor Network (USA), Brain Tumor Resource and Information Network (USA), Bristol-Myers Squibb (BMS), Celldex Therapeutics, Crusade, Dijon Designs (UK), Elekta, Eli Lilly, Gerry & Nancy Pencer Brain Trust (Canada), Gosling Foundation (UK), GlaxoSmithKline (GSK), Ivy Foundation (USA), Lilly, Link Pharmaceuticals, Magforce, Medac, Merck Serono, Merck, MGI Pharma, MSD Oncology, NeoPharm, Neuroendoscopy (Australia), Northwest Biotherapeutics, Novartis, Novocure, Pediatric Brain Tumor Foundation (USA), Pfizer, Photonamic, Roche, Schering-Plough (Global), Sontag Foundation (USA), Spink (UK), to-BBB, Vane Percy (UK), VBL Therapeutics, Wallerstein Foundation (USA).
  • Pentheroudakis George: No conflicts of interest to declare
  • Plataniotis George: No conflicts of interest to declare
  • Plate Ananda: No disclosure at time of going online
  • Provenzano Salvatore: No conflicts of interest to declare
  • Rapetti Simonetta: No disclosure at time of going online
  • Rauh Stefan: No conflicts of interest to declare
  • Senkus Elzbieta: Receipt of grants/research support: Amgen, Astellas, AstraZeneca, Bayer, BMS, Janssen, Pfizer, Pierre Fabre, Roche; Other support (travel expenses): Amgen, Astellas, AstraZeneca, Bayer, BMS, Janssen, Pfizer, Novartis, Roche
  • Sessa Cristiana: No conflicts of interest to declare
  • Seufferlein Thomas: No conflicts of interest to declare
  • Spanic Tanja: No conflicts of interest to declare​
  • Spurrier Gilliosa: MelanomeFrance has received project funding from Roche, Novartis, BMS, Amgen - Support never includes editorial rights or influence on MelanomeFrance’s programme or activities; GS has received Patient Advocate Honoraria for Advisory boards from Amgen, BMS and Novartis
  • Stacchiotti Silvia: Research grants: Novartis, Pfizer, PharmaMar, GlaxoSmithKline, Amgen, Bayer
  • Stahl Michael: No conflicts of interest to declare
  • Stupp Roger: Honoraria or consulting fee (paid to institution): Roche, Merck KGaA/EMD-Serono, MSD/Merck & Co, Pfizer, Ipsen Pharma, Novartis.
  • Tanay Mary: No conflicts of interest to declare
  • Tassini Umberto: No conflicts of interest to declare
  • Ugarte Ana: No conflicts of interest to declare
  • Vallejo Ana: No disclosure at time of going online
  • Vallone Stefania: No conflicts of interest to declare
  • Van Cutsem Eric: Research funding – Amgen, MerckSerono, Phizer, Roche, Sanofi-Aventis
  • van der Grient-Logtenberg Hilje: No conflicts of interest to declare
  • van Thiel Ingo: No conflicts of interest to declare
  • Verslype Chris: Research funding – Bayer, Sirtex, Novartis
  • Waldmann Anita: No conflicts of interest to declare
  • Wartenberg Markus: No disclosure at time of going online
  • Wilson Roger: No disclosure at time of going online
  • Zwinkels Hanneke: No conflicts of interest to declare